

Glycinocins E–H, Antimicrobial Lipopeptides Produced by a *Streptomyces* Strain

Ignacio Fernández-Pastor,* Victor González-Menéndez, Ignacio González, Pilar Sanchez, Rachel Serrano, Thomas A Mackenzie, Daniel Oves-Costales, Manuel Casares Porcel, Olga Genilloud, and Fernando Reyes*



Cite This: *J. Nat. Prod.* 2025, 88, 2127–2137



Read Online

ACCESS |



Metrics & More




Article Recommendations



Supporting Information

ABSTRACT: In an antifungal screening of extracts from microbial strains isolated from gypsum outcrops in Granada, Spain, four new cyclic lipopeptides, glycinocins E–H (1–4), were identified from *Streptomyces* sp. CA-297274 and exhibited potent activity against *Zymoseptoria tritici*, the causal agent of septoria tritici blotch of wheat. Isolation and structure elucidation performed using HR-MS/MS, 1D and 2D NMR, and Marfey's analyses, revealed that structures contained an Asp-Gly-Asp-Gly motif in the peptide scaffold, typical of calcium-dependent antibiotics. Genome sequencing and bioinformatic analysis of the strain uncovered a biosynthetic gene cluster consistent with the production of these compounds and helped to correct the absolute configuration determined by Marfey's analysis of some amino acid residues. The isolated metabolites displayed notable antifungal activity against *Z. tritici*, with minimum inhibitory concentration values in the micromolar range (Compound 4, 9.5 μ M), and calcium-dependent antibacterial activity against methicillin-resistant *Staphylococcus aureus* (5.2 μ M for 4) and vancomycin-resistant *Enterococcus faecium* (3.0 μ M for 4), as anticipated by their structural analysis. Glycinocins E–H displayed no cytotoxicity against the human liver cancer cell line HepG2. These findings expand the chemical diversity of calcium-dependent antibiotics and highlight the ecological and therapeutic potential of extremophile-derived actinomycetes as a source of novel bioactive compounds.



Cyclic lipopeptides have attracted significant attention as promising starting points for the development of novel antibiotics and antifungal drugs.^{1–3} The characterization of this structural class traces back to the 1950s when amphomycin was first isolated.^{4,5} Compounds of this structural class have been isolated from several bacterial and fungal genera and include compounds such as the calcium dependent antibiotics daptomycin and malacidin, broad spectrum antifungal compounds such as hassallidins, laxaphycins, and pneumocandins, or the surfactants, one of the most effective biosurfactants available.^{6–12} Acidic amino acids in the peptide core confer to these compounds activity as biosurfactants due to the presence of a lipophilic acyl chain linked to a hydrophilic oligopeptide. Biological activity displayed by some acidic cyclic lipopeptides can be mostly ascribed to their amphipathic molecular nature.^{13,14} Regarding their antimicrobial activity, different modes of action, such as depolarization in the lipidic cell membrane or interaction with intracellular components, enzymes, or proteins, have been reported.^{15–17} A particular class of cyclic lipopeptides is those described as calcium-dependent antibiotics (CDAs). Structurally, this class is characterized by the presence in their structures of a highly conserved Asp-X-Asp-Gly motif. This sequence plays a main role in calcium binding, which is essential for achieving optimal

antibacterial activity. In the absence of calcium, the activity of CDAs is significantly weakened.^{18–20} It has been reported that organisms that evolved in high-calcium environments have developed a defensive tool producing this kind of bioactive metabolite.²¹

The arid zone located in the south of the Iberian Peninsula is characterized by its dry and warm climate with extensive zones have marl and gypsum-marl soils.²² These extreme environmental conditions can only be colonized by highly specialized organisms.^{23–25} Extremophile microbes residing in these soils or added externally can adapt to such extreme environments, this success being related to a large biosynthetic versatility and the production of specialized metabolites.^{26–28} In this sense, this hotspot constitutes a good starting point for the hunt for new compounds with antibiotic or agrochemical interest.

Received: June 16, 2025


Revised: August 14, 2025

Accepted: August 15, 2025

Published: August 22, 2025



During our exploration of antifungal molecules from gypsum-soil-associated bacteria, a chemical investigation of *Streptomyces* sp. CA-297274 resulted in the isolation and identification four new cyclic lipopeptides included in the family of the glycinocins.²⁹ These peptides are characterized by possessing a cyclic structure of nine amino acids linked via a 2,3-diaminopropionic acid (Dap) with an aspartic acid unit, which is in turn connected to a fatty acid moiety. All members of this family of compounds contain the canonical calcium binding motif Asp-Gly-Asp-Gly. The objective of this study was to characterize the chemical structures and biological activities of these new compounds and to assess their potential as antimicrobial agents.



RESULTS AND DISCUSSION

Glycinocins E–H (1–4) were obtained by culturing the strain CA-297274 in medium M016 followed by extraction of the cultures with acetone. Antifungal assays of the crude acetone extracts revealed activity against *Z. tritici*, triggering further investigation of the metabolites produced by this strain. The crude extract was fractionated by semipreparative HPLC, antifungal activity of the fractions was determined, and bioactive fractions were analyzed by LC-HRMS/MS. De-replication against public or commercial databases (Dictionary of Natural Products³⁰, COCONUT,³¹ or GNPS³²) revealed no matches for the detected molecular formula associated to the main peaks. Mass spectra revealed a fragmentation pattern typical of a lipopeptide with a peptide core composed of 11 amino acids and an acyl side chain (Figure 1). The calculated molecular formulas for the four congeners differed only in successive methylene additions (Figures S2–S14).

Glycinocin E (1) was obtained as a white, amorphous solid. A molecular formula of $C_{57}H_{90}N_{12}O_{18}$ was deduced by (+)-ESI-TOF analysis ($[M + H]^+$ at m/z 1231.6567, calcd 1231.6574). Interpretation of the 1H and ^{13}C NMR spectra (500 and 150 MHz, respectively, DMSO- d_6 , at 24 °C) in conjunction with bidimensional COSY, NOESY, TOCSY, HSQC, and HMBC NMR data allowed us to identify the presence of Asp, Dap, Pro, Ile, Val, Gly, and pipecolic acid (Pipe) (Tables 1 and 2). The ^{13}C NMR spectrum displayed fifteen carbonyl carbon signals between δ_C 172.4 and 165.6; two sp^2 methine carbons at δ_C 143.7 and 124.4, eleven sp^3 methine signals (eight from the αC of the chiral amino acids between δ_C 60.0 and 47.6, two from the Val and Ile at δ_C 30.9 and 35.6, respectively, and one from the acyl side chain at δ_C 27.6), twenty-three sp^2 methylene signals (three from the αC of the Gly residues and the remaining twenty assigned to the different amino acid side chains and the lipidic chain, all resonating at δ_C between 47.5 and 20.7), and finally six methyl signals (two from Ile, two from Val, and two from the fatty acid




Figure 1. Scheme and MS/MS fragmentation of 1.

Table 1. ^1H and ^{13}C NMR (500 MHz; 125 MHz; $\text{DMSO}-d_6$; 24°C) Data of Compounds 1 and 2

| Residue | 1 | | | 2 | | |
|---------|------------|--|--|------------|--|--|
| | Position | ^1H NMR: δ in ppm, mult (J in Hz) | ^{13}C NMR: δ in ppm, type | Position | ^1H NMR: δ in ppm, mult (J in Hz) | ^{13}C NMR: δ in ppm, type |
| FA | CO | | 165.2, C | CO | | 165.3, C |
| | 2 | 5.92, d (15.4) | 124.2, CH | 2 | 5.92, d (15.4) | 124.3, CH |
| | 3 | 6.63, dt (15.4, 8.6) | 143.7, CH | 3 | 6.63, dt (15.4, 8.6) | 143.7, CH |
| | 4 | 2.12, (8.6, 6.8) | 31.7, CH_2 | 4 | 2.12, (8.6, 6.8) | 31.6, CH_2 |
| | 5 | 1.35, m | 28.1, CH_2 | 5 | 1.38, m | 28.1, CH_2 |
| | 6 | 1.24, m | 29.3, CH_2 | 6 | 1.25, m | 29.2, CH_2 |
| | 7–9 | 1.23–1.25, m | 29.1–29.7, CH_2 | 7–10 | 1.21–1.25, m | 29.1–29.4, CH_2 |
| | 10 | 1.23, m | 26.8, CH_2 | 10 | 1.23, m | 26.8, CH_2 |
| | 11 | 1.12, m | 38.8, CH_2 | 11 | 1.11, m | 38.8, CH_2 |
| | 12 | 1.46, hept | 27.6, CH | 12 | 1.27, m | 34.2, CH |
| | 13, 14 | 0.82, d | 22.9, CH_3 | 12-Me | 0.80, m | 11.6, CH_3 |
| Asp 1 | | | | 13 | 1.05, m | 36.3, CH_2 |
| | | | | | 1.25, m | |
| | | | | 14 | 0.82 | 23.0, CH_3 |
| | NH | 8.15 | | NH | 8.15 | |
| | CO | | 170.6, C | CO | | 170.5, C |
| Dap | α | 4.60, m | 49.6, CH | α | 4.61, m | 49.7, CH |
| | β | 2.49, m | 36.4, CH_2 | β | 2.49, m | 36.4, CH_2 |
| | | 2.62, m | | | 2.65, m | |
| | γ | | 172.3, C | γ | | 172.3, C |
| | NH | 8.22, m | | NH | 8.22, m | |
| Pipe | CO | | 170.5, C | CO | | 170.5, C |
| | α | 4.65, m | 49.1, CH | α | 4.65, m | 49.1, CH |
| | β | 3.09, m | 40.1, CH_2 | β | 3.06, m | 40.1, CH_2 |
| | | 3.55, m | | | 3.54, m | |
| | β NH | 7.50, m | | β NH | 7.50, m | |
| Gly4 | CO | | 170.8, C | CO | | 170.8, C |
| | α | 4.75, m | 56.4, CH | α | 4.73, m | 56.5, CH |
| | β | 1.50, m | 27.0, CH_2 | β | 1.50, m | 26.9, CH_2 |
| | | 2.18, m | | | 2.18, m | |
| | γ | 1.35, m | 20.7, CH_2 | γ | 1.37, m | 20.7, CH_2 |
| | | 1.52, m | | | 1.54, m | |
| | δ | 1.21, m | 24.7, CH_2 | δ | 1.21, m | 24.9, CH_2 |
| | | 1.51, m | | | 1.51, m | |
| | ϵ | 2.83, m | 40.2, CH_2 | ϵ | 2.84, m | 40.2, CH_2 |
| | | 4.35, m | | | 4.35, m | |
| Asp5 | NH | 8.10, m | | NH | 8.08, m | |
| | CO | | 169.6, C | CO | | 169.6, C |
| | α | 3.62, m | 42.1, CH_2 | α | 3.64, m | 42.1, CH_2 |
| | | 3.99, m | | | 3.80, m | |
| Gly6 | NH | 8.27, m | | NH | 8.27, m | |
| | CO | | 171.2, C | CO | | 171.2, C |
| | α | 4.63, m | 48.7, CH | α | 4.63, m | 48.8, CH |
| | β | 2.54, m | 36.1, CH_2 | β | 2.54, m | 36.1, CH_2 |
| | γ | | 172.2, C | γ | | 172.2, C |
| Asp7 | NH | 8.20, m | | NH | 8.21, m | |
| | CO | | 169.8, C | CO | | 169.8, C |
| | α | 3.75, m | 40.7, CH_2 | α | 3.75, m | 40.7, CH_2 |
| | | | | | | |
| Gly8 | NH | 8.29, m | | NH | 8.29, m | |
| | CO | | 170.9, C | CO | | 170.9, C |
| | α | 4.49, m | 50.3, CH | α | 4.49, m | 50.3, CH |
| | β | 2.53, m | 36.7, CH_2 | β | 2.53, m | 36.7, CH_2 |
| | | 2.73, m | | | 2.71, m | |
| Val | γ | | 172.1, C | γ | | 172.1, C |
| | NH | 7.84, m | | NH | 7.83, m | |
| | CO | | 168.8, C | CO | | 168.8, C |
| | α | 3.70, m | 42.1, CH_2 | α | 3.70, m | 42.1, CH_2 |
| | | 3.79, m | | | 3.80, m | |
| | NH | 7.86, m | | NH | 7.86, m | |

Table 1. continued

| Residue | 1 | | | 2 | | |
|---------|-------------|---|--|-------------|---|--|
| | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type |
| Ile | CO | | 171.1, C | CO | | 171.1, C |
| | α | 4.17, m | 58.3, CH | α | 4.18, m | 58.1, CH |
| | β | 1.93, m | 30.9, CH | β | 1.93, m | 30.9, CH |
| | γ | 0.82, m | 18.6, CH ₃ | γ | 0.82, m | 18.6, CH ₃ |
| | γ' | 0.82, m | 19.4, CH ₃ | γ' | 0.82, m | 19.4, CH ₃ |
| | NH | 7.88, m | | NH | 7.87, m | |
| | CO | | 170.7, CH ₃ | CO | | 170.7, C |
| | α | 4.30, m | 54.4, CH | α | 4.30, m | 54.5, CH |
| | β | 1.78, m | 35.6, CH | β | 1.72, m | 36.3, CH |
| | γ | 1.08, m | 24.6, CH ₂ | γ | 1.08, m | 24.6, CH ₂ |
| Pro | | 1.45, m | | | 1.45, m | |
| | δ | 0.78, m | 10.8, CH ₃ | δ | 0.78, m | 10.7, CH ₃ |
| | β -Me | 0.85, m | 15.1, CH ₃ | β -Me | 0.85, m | 15.2, CH ₃ |
| | CO | | 172.2, C | CO | | 172.3, C |
| | α | 4.15, m | 59.9, CH | α | 4.15, m | 59.9, CH |
| | β | 1.74, m | 29.7, CH ₂ | β | 1.71, m | 29.9, CH ₂ |
| | | 2.01, m | | | 1.98, m | |
| | γ | 1.79, m | 24.8, CH ₂ | γ | 1.77, m | 24.8, CH ₂ |
| | | 1.93, m | | | 1.90, m | |
| | δ | 3.52, m | 47.5, CH ₂ | δ | 3.51, m | 47.5, CH ₂ |
| | | 3.79, m | | | 3.78, m | |

chain between δ_C 22.9 and 10.8). The ¹H spectra of compound **1** exhibited ten signals of amide exchangeable hydrogens between δ_H 8.3 and 7.7 ppm. The lipophilic moiety of the peptide was identified as *E*-12-methyltridec-2-enoic acid (MTEA) using COSY and HMBC correlations and comparison of the NMR data with those reported for other glycinocins.²⁹ A coupling constant between the sp² methine hydrogens of 15.4 Hz confirmed an *E* configuration for the double bond. The connection between amide hydrogens and α C of the amino acids was deduced from the COSY spectrum. The chemical shifts of the side chain of each amino acid were determined by TOCSY NMR data, following the cross peaks from amide hydrogens and α C hydrogens. Inter-residue connection and amino acid sequence were deduced from key NOESY correlations between the amide hydrogen of each amino acid and the α C hydrogen of the adjacent amino acid (Figure 2). The link between the acyl side chain and the aspartic residue was established by the presence of a NOESY cross peak between the hydrogen of the α C of the acyl side chain at δ_H 5.92 and the amide hydrogen of the first Asp residue at δ_H 8.15. HMBC combined with NOESY spectra determined the attachment of the first Asp residue to Dap, linking the side chain with the cyclic peptidic core. HRMS/MS data additionally confirmed the following sequence MTEA-Asp-Dap-Pipe-Gly-Asp-Gly-Asp-Gly-Val-Ile-Pro (Figure 1). The HSQC spectrum reveals the presence of two conformations for the Pipe residue (Figures S28 and S29). The presence of various conformers has been described for other similar peptides such as laspartomycin C, a diastereoisomer of glycinocin A.³³ A comparison of laspartomycin C with **1** revealed its high structural similarity. Key differences include the presence of D-Thr in laspartomycin C instead of D-Val in **1** and minor differences in the FA chain. According to the NMR data, the two tertiary amide bonds in cyclic amino acids were found to have a *trans* geometry for Pro and *cis* for Pipe in the major conformer. This was supported by the chemical shifts of β C (δ_C 29.7) and γ C (δ_C 24.8) of the Pro residue.³⁴ The NMR

signals observed at α C δ_H 4.75/ δ_C 56.4 and ϵ C δ_H 2.86, 4.33/ δ_C 39.9 positions of Pipe compared with rapamycin rotamers confirmed that it was in the *cis* configuration.³⁵ Only the chemical shifts for the main conformer are detailed in Tables 1 and 2. Chemical shifts for minor conformers are included in Tables S2 and S3.

The molecular formula of glycinocin F (**2**) was established as C₅₈H₉₂N₁₂O₁₈ by (+)-ESI-TOF analysis ([M + H]⁺ at *m/z* 1245.6710, calcd 1245.6730). This formula accounted for an additional sp³ methine in the lipidic chain compared to **1**; ESI-TOF analysis, together with COSY and HMBC correlations confirmed the presence of a *E*-12-methyltetradec-2-enoic acid unit in the molecule.

Glycinocin G (**3**) presented the molecular formula C₅₉H₉₄N₁₂O₁₈ according to (+)-ESI-TOF analysis ([M + H]⁺ at *m/z* 1259.6883, calcd 1259.6887). Compared to **2**, the NMR spectra of **3** showed key signals in HSQC accounting for the absence of the sp³ methylene signal of Dap and a new sp³ methine signal, suggesting the replacement of Dap with a Dab residue, which was confirmed by COSY correlations. This replacement of a Dap with a Dab residue seems to provide additional rigidity to the structure, making the differences between the conformers more evident in the NMR spectra (Figure S45). Finally, glycinocin H (**4**) presented the molecular formula C₆₀H₉₆N₁₂O₁₈ ([M + H]⁺ at *m/z* 1273.7018, calcd 1273.7043 according to (+)-ESI-TOF data). Comparison of the HSQC NMR data obtained for **4** with those of **3** revealed that it possesses the same peptide core and a different lipidic chain, identified as *E*-14-methylpentadec-2-enoic acid, as confirmed by analysis of the ESI-TOF and COSY data.

A comparison of **1**–**4** with the previously described glycinocins A–D (**5**–**8**) revealed key differences including the presence of D-Val₅ in **1**–**4** instead of D-*allo*-Thr₅ conserved in glycinocins A–D; in addition compounds **3** and **4** exhibit a residue of 2,3-diaminobutanoic acid (Dab) replacing the Dap

Table 2. ¹H and ¹³C NMR (500 MHz; 125 MHz; DMSO-*d*₆; 24°C) Data of Compounds 3 and 4

| Residue | 3 | | | 4 | | |
|---------|-------------|---|--|-------------|---|--|
| | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type |
| FA | CO | | 165.3, C | CO | | 165.2, C |
| | 2 | 5.92, d (15.4) | 124.3, CH | 2 | 5.92, d (15.4) | 124.2, CH |
| | 3 | 6.63, dt (15.4, 8.6) | 143.7, CH | 3 | 6.63, dt (15.4, 8.6) | 143.9, CH |
| | 4 | 2.12, (8.6, 6.8) | 31.6, CH ₂ | 4 | 2.12, (8.6, 6.8) | 31.6, CH ₂ |
| | 5 | 1.38, m | 28.1, CH ₂ | 5 | 1.35, m | 28.2, CH ₂ |
| | 6 | 1.25, m | 29.3, CH ₂ | 6 | 1.24, m | 29.1, CH ₂ |
| | 7–10 | 1.21–1.25, m | 29.1–29.4, CH ₂ | 7–11 | 1.23–1.25, m | 29.1–29.7, CH ₂ |
| | 10 | 1.23, m | 26.8, CH ₂ | 12 | 1.23, m | 26.9, CH ₂ |
| | 11 | 1.11, m | 38.8, CH ₂ | 13 | 1.12, m | 38.8, CH ₂ |
| | 12 | 1.27, m | 34.2, CH ₂ | 14 | 1.46, hept | 27.7, CH ₂ |
| | 12-Me | 0.80, m | 11.6, CH ₃ | 15, 16 | 0.82, d | 22.8, CH ₃ |
| | 13 | 1.05, m | 36.4, CH ₂ | | | |
| | | 1.25, m | | | | |
| | 14 | 0.82, t | 23.0, CH ₃ | | | |
| Asp1 | NH | 8.15, m | | NH | 8.16, m | |
| | CO | | 170.9, C | CO | | 171.8, C |
| | α | 4.71, m | 49.8, CH | α | 4.68, m | 49.8, CH |
| | β | 2.49, m | 36.2, CH ₂ | β | 2.50, m | 36.3, CH ₂ |
| Dab | | 2.65, m | | | 2.68, m | |
| | γ | | 171.9, C | γ | | 170.7, C |
| | NH | 8.02, m | | NH | 8.01, m | |
| | CO | | 170.5, C | CO | | n.d., C |
| | α | 4.96, m | 53.3, CH | α | 4.94, m | 53.2, CH |
| | β | 4.27, m | 45.8, CH | β | 4.25, m | 45.9, CH |
| | | | 17.7, CH ₃ | | | 17.6, CH ₃ |
| | β -Me | 0.97, d | | β -Me | 0.97, d | |
| Pipe | β NH | 7.42, m | | β NH | 8.03, m | |
| | CO | | 170.8, C | CO | | 170.8, C |
| | α | 4.98, m | 57.3, CH | α | 4.97, m | 56.5, CH |
| | β | 1.50, m | 26.9, CH ₂ | β | 1.47, m | 27.1, CH ₂ |
| | | 2.23, m | | | 2.21, m | |
| | γ | 1.37, m | 20.7, CH ₂ | γ | 1.28, m | 20.7, CH ₂ |
| | | 1.54, m | | | 1.47, m | |
| | δ | 1.21, m | 24.9, CH ₂ | δ | 1.21, m | 25.1, CH ₂ |
| | | 1.51, m | | | 1.51, m | |
| | ϵ | 3.16, m | 43.8, CH ₂ | ϵ | 3.16, m | 43.7, CH ₂ |
| | | 3.83, m | | | 3.82, m | |
| | | 8.08, m | | | 8.08, m | |
| Gly4 | NH | | | NH | | |
| | CO | | 169.6, C | CO | | n.d., C |
| | α | 3.64, m | 42.1, CH ₂ | α | 3.64, m | 42.5, CH ₂ |
| Asp5 | | 3.80, m | | | 3.80, m | |
| | NH | 8.27, m | | NH | 8.27, m | |
| | CO | | 171.2, C | CO | | 170.9, C |
| | α | 4.53, m | 49.9, CH | α | 4.60, m | 49.6, CH |
| | β | 2.54, m | 36.1, CH ₂ | β | 2.50, m | 36.1, CH ₂ |
| | | | | | 2.71, m | |
| | γ | | 172.2, C | γ | | 172.2, C |
| | NH | 8.21, m | | NH | 8.22, m | |
| Gly6 | CO | | 169.8, C | CO | | n.d., C |
| | α | 3.75, m | 42.3, CH ₂ | α | 3.75, m | 40.7, CH ₂ |
| | | | | | | |
| Asp7 | NH | 8.29, m | | NH | 8.28, m | |
| | CO | | 170.9, C | CO | | 170.9, C |
| | α | 4.44, m | 50.2, CH | α | 4.47, m | 50.2, CH |
| | β | 2.53, m | 36.7, CH ₂ | β | 2.53, m | 36.70, CH ₂ |
| | | 2.70, m | | | 2.71, m | |
| | γ | | 172.1, C | γ | | 172.05, C |
| | NH | 7.84, m | | NH | 7.83, m | |
| | CO | | 168.8, C | CO | | 169.0, C |
| Gly8 | α | 3.70, m | 42.1, CH ₂ | α | 3.70, m | 42.4, CH ₂ |
| | | | | | | |

Table 2. continued

| Residue | 3 | | | 4 | | |
|---------|-------------|---|--|-------------|---|--|
| | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type | Position | ¹ H NMR: δ in ppm, mult (<i>J</i> in Hz) | ¹³ C NMR: δ in ppm, type |
| Val | | 3.79, m | | | 3.80, m | |
| | NH | 7.85, m | | NH | 7.85, m | |
| | CO | | 171.5, C | CO | | 171.0, C |
| | α | 4.16, m | 58.4, CH | α | 4.17, m | 58.3, CH |
| | β | 1.90, m | 31.0, CH | β | 1.94, m | 30.7, CH |
| Ile | γ | 0.81, m | 18.5, CH ₃ | γ | 0.79, m | 18.4, CH ₃ |
| | γ' | 0.81, m | 19.5, CH ₃ | γ' | 0.80, m | 19.5, CH ₃ |
| | NH | 7.88, m | | NH | 7.86, m | |
| | CO | | 170.7, C | CO | | 170.5, C |
| | α | 4.30, m | 54.5, CH | α | 4.28, m | 54.7, CH |
| Pro | β | 1.72, m | 36.3, CH | β | 1.77, m | 35.5, CH |
| | γ | 1.08, m | 24.8, CH ₂ | γ | 1.11, m | 24.8, CH ₂ |
| | | 1.45, m | | | 1.45, m | |
| | δ | 0.79, m | 10.7, CH ₃ | δ | 0.77, m | 10.9, CH ₃ |
| | β -Me | 0.91, m | 15.2, CH ₃ | β -Me | 0.90, m | 15.3, CH ₃ |
| | CO | | 172.3, C | CO | | n.d., C |
| | α | 4.06, m | 60.5, CH | α | 4.15, m | 59.9, CH |
| | β | 1.62, m | 29.9, CH ₂ | β | 1.74, m | 29.7, CH ₂ |
| | | 2.08, m | | | 1.99, m | |
| | γ | 1.76, m | 25.3, CH ₂ | γ | 1.76, m | 25.0, CH ₂ |
| | | 1.88, m | | | 1.86, m | |
| | δ | 3.43, m | 47.5, CH ₂ | δ | 3.43, m | 47.7, CH ₂ |
| | | 3.73, m | | | 3.78, m | |




Figure 2. Key NOESY correlations observed for compounds 1–4.

moiety present in glycinocins A–D, together with minor differences in the FA chain.

The absolute configuration of **1** was determined by Marfey's analysis allowing us to establish absolute configuration of all chiral centers in the peptide as L-Asp-L-Dap-D-Pipe-Gly-L-Asp-Gly-L-Asp-Gly-D-Val-L-Ile-L-Pro (Figures S51 and S52). In an initial attempt to determine its absolute configuration,

compound **1** was hydrolyzed at 120 °C, obtaining a 2:1 ratio of L-Asp and D-Asp, not in agreement with the prediction of configuration indicated by Biosynthetic Gene Cluster (BGC) analysis (Figure S53). Marfey's analysis hydrolysis was therefore performed at 80 °C, which avoided racemization, obtaining only a single peak of L-Asp. Assuming that the *S* configuration determined for the α C in Dab is conserved in the α C of the Dap, the configuration of the Dab β C chiral center was determined as *S* by the coupling constant between α H and β H (*J* = 7.7 Hz) and a NOESY correlation observed between β -Me and α -NH.^{36–38}

In addition, the absolute configuration of both chiral centers in the Ile residue was determined by analysis of the HSQC spectrum of an aliquot of the hydrolysate of **1**, previously prepared for the Marfey's analysis, and comparison with standards of L-Ile and L-*allo*-Ile. This experiment confirmed the presence of L-Ile in the molecule (Figures S54 and S55).

To independently confirm the configuration of the peptide-based backbone, we performed whole genome sequencing of the producing microorganism. The genome sequence of strain *Streptomyces* sp. CA-297274 was deposited at NCBI (Bio-




Figure 3. Proposed NRPS assembly line for glycinocin biosynthesis. The adenylation domain substrate specificity predicted by antiSMASH is included in each of the modules.

Sample accession number SAMN50185168). Identification of the putative BGC responsible for glycinocin production was straightforward due to the high level of similarity to that of laspartomycin.³⁹ Bioinformatic analysis of the BGC, specifically of the non-ribosomal peptide synthetases (NRPSs) (Figure 3), allowed us to identify epimerization domains (E) in modules 3 (pipecolic acid selection) and 9 (valine selection). As expected, the condensation domains from modules 4 and 10 belong to the ^DC_L subtype and catalyze the condensation of an upstream T-loaded D-amino acid with a downstream T-loaded L-amino acid. The starter condensation domain from module 1 is responsible for the attachment of the fatty acid chain to the free amino group from the aspartic residue loaded in module 1. The other condensation domains belong to the ^LC_L subtype, in accordance with the expected S configuration for the remaining amino acids, as determined in the Marfey's analysis.

The cytotoxic activity of compounds 1–4 was evaluated against five human tumoral cell lines, and no activity was observed at the highest concentration tested (40 µg/mL for 1–3 and 5 µg/mL for 4). Characterization of the antifungal properties of glycinocins E–H was carried out by testing fungal growth inhibition (absorbance) and cell viability (fluorescence) against *Z. tritici* CBS 115943 (Table 3). The antifungal

Table 3. Minimum Inhibitory Concentration (MIC) Values in µM for Compounds 1–4 and Amphotericin B against *Z. tritici* Based on Absorbance and Fluorescence In Vitro Assays

| Compound | Absorbance (growth inhibition) | Fluorescence (cell viability) |
|----------------|--------------------------------|-------------------------------|
| 1 | 86.3 | 63.3 |
| 2 | 82.9 | 69.1 |
| 3 | 39.8 | 32.5 |
| 4 | 9.5 | 7.2 |
| amphotericin B | 1.5 | 1.3 |

compound amphotericin B was used as a positive control. Compound 4 with the longer fatty acid chain and a Dap residue in its structure displayed the highest potency of the series, with a MIC against *Z. tritici* of 9.5 µM based on fungal growth inhibition and 7.2 µM based on cell viability. Compound 3 displayed weaker activity (Table 3), and compounds 1 and 2, with a Dap instead of a Dab residue in their structure displayed even weaker antifungal potency against *Z. tritici* (Table 3).

Glycinocins A–D have been reported as acidic cyclo-lipopeptide antibiotics structurally related to the clinically approved drug daptomycin. These compounds exhibit calcium-dependent antimicrobial activity against *Staphylococcus aureus* and *Bacillus subtilis*, but no antifungal activity has been reported earlier for these compounds.⁴⁰

The most widely used fungicides to control *Z. tritici* have a single target site mode of action, including azoles, succinate dehydrogenase inhibitors, and quinone outside inhibitors, all of which have resistance events documented, highlighting the current need to discover new effective antifungals against this pathogen.⁴¹ In this sense, compound 4 is an acidic cyclo-lipopeptide representing a novel structure with an unknown mode of action suggesting that other structural classes of compounds could be explored as an alternative solution to treat infections associated the causal agent of septoria tritici

blotch, one of the European Union's most devastating foliar diseases of wheat.

Because glycinocins A–D are compounds with a proven calcium-dependent antimicrobial activity against Gram positive bacteria and due to the presence of an Asp-Gly-Asp-Gly motif in the peptide scaffold of glycinocins E–H, we evaluated their antibacterial activity against methicillin-resistant *Staphylococcus aureus* (MRSA) and vancomycin-resistant *Enterococcus faecium* Van A (VRE) in the presence or absence calcium to confirm and compare their calcium-dependent antimicrobial activity (Table 4).

Table 4. Minimum Inhibitory Concentration (MIC) Values in µM for Compounds 1–4 against Methicillin-Resistant *S. aureus* (MRSA) and Vancomycin-Resistant *E. faecium* (VRE)

| Compound | MRSA | MRSA + CaCl ₂ ^a | VRE | VRE + CaCl ₂ ^a |
|------------|------|---------------------------------------|------|--------------------------------------|
| 1 | 94.0 | 9.5 | >205 | 18.7 |
| 2 | 35.0 | 2.5 | 71.7 | 3.9 |
| 3 | 11.3 | 4.8 | 25.9 | 3.1 |
| 4 | 12.0 | 5.2 | 21.3 | 3.0 |
| daptomycin | 33.0 | 8.5 | >155 | 6.1 |

^a[CaCl₂] = 3.0 mM.

The compounds exhibited moderate antibacterial activities against methicillin-resistant *S. aureus* (MRSA MB5393) and vancomycin-resistant *E. faecium* (VanA-VRE) in the absence of Ca²⁺ ions. However, the antibacterial activity of all of the compounds tested was strongly improved in the presence of CaCl₂. Interestingly, compounds 2–4 displayed higher potency than the daptomycin control in these assays. These findings are in agreement with the reported activity of synthesized glycinocins A–C, which exhibited calcium-dependent antimicrobial activity against *Staphylococcus aureus* with MIC values ranging from 5.5 to 17 µM.⁴² These results clearly confirmed the calcium-dependent antibacterial activity of glycinocins E–H. The structural differences among glycinocins E–H (1–4), particularly in the length of the fatty acid chain and the substitution of Dap with Dab in the peptide core, although seemingly minor, have notable impacts on biological activity. Glycinocin H (4), which contains a longer fatty acid tail and a Dab residue, exhibited the most potent antimicrobial activity, suggesting that increased hydrophobicity enhances the membrane interaction and calcium-dependent activity. In contrast, analogs with shorter or saturated fatty acid chains or those containing Dap instead of Dab showed reduced potency, highlighting the critical role of both lipid tail composition and basic amino acid identity in modulating antimicrobial efficacy. A similar structure–activity relationship has been reported for other lipopeptides, such as daptomycin, whose antimicrobial activity is abolished in analogs with shorter lipid chains but retained or enhanced when the chain length is increased.^{43–45}

In this study, the discovery of four new cyclic lipopeptides, glycinocins E–H (1–4), from *Streptomyces* sp. CA-297274, isolated from gypsum-rich soil in Granada, Spain, is reported. Identified through LC/HRMS-guided antifungal screening, these compounds showed potent activity against *Zymoseptoria tritici*. Structural elucidation using HR-MS/MS, NMR, and Marfey's analysis revealed a conserved Asp-Gly-Asp-Gly motif typical of calcium-dependent antibiotics (CDAs), and genome analysis confirmed a matching biosynthetic gene cluster and

refined configuration assignments. Glycinocins E–H displayed antifungal and calcium-dependent antibacterial activity against resistant strains like MRSA and VRE, with no observed cytotoxicity toward the HepG2 cancer cell line.

The discovery of calcium-dependent antibiotics from an actinomycete strain found in gypsum-rich soil might be coincidental; it is a noteworthy observation that complements ongoing efforts to understand the ecological factors influencing secondary metabolite production.⁴⁶ This work highlights the potential of extremophile-derived actinomycetes as a source of novel bioactive compounds. This environmental adaptation could offer a selective advantage, fine-tuning the biological activity of secondary metabolites such as CDAs in situ. Glycinocins E–H expand the growing class of CDAs with dual antifungal and antibacterial properties, reinforcing their potential relevance in both medical and agricultural applications.

EXPERIMENTAL SECTION

General Experimental Procedures. All solvents employed were of HPLC grade. Optical rotations were measured on a Jasco P-2000 polarimeter. IR spectra were recorded with a JASCO FT/IR-4100 spectrometer. LC-UV-LRMS analyses were performed on an Agilent 1260 Infinity II single quadrupole LC-MS system. HR-ESIMS and MS/MS spectra were acquired using a Bruker maXis QTOF mass spectrometer coupled to an Agilent 1200 Rapid Resolution HPLC. The mass spectrometer was operated in positive and negative mode. Preparative or semi-preparative HPLC purifications were performed on a Gilson GX-281 322H2 HPLC using a PrepHT Zorbax SB-C₁₈ (21.2 × 250 mm², 7 μm) and SemiPrepHt Zorbax, RX-C₁₈ (10 × 150 mm², 5 μm) columns. Mono- and bidimensional Nuclear Magnetic Resonance (NMR) spectra were recorded at 297 K on a Bruker Avance III spectrometer (500 and 125 MHz for ¹H and ¹³C, respectively) equipped with a 1.7 mm TCI MicroCryoProbe. Chemical shifts from ¹H and ¹³C were reported in parts per million using the signals of the residual non-deuterated solvent as internal reference (δ_{H} 2.50 and δ_{C} 39.52 ppm for DMSO-*d*₆).

Producing Microorganisms and Large-Scale Fermentation of *Streptomyces* sp. CA-297274. The strain CA-297274 was isolated from a gypsum outcrop sample collected beneath specimens of the lichen *Gyalolechia fulgida* in a dry area in Esczar (Granada, Spain). Based on its complete 16S rDNA sequence (1492 bp), the strain CA-297274 was associated to the species *Streptomyces apricus* SUN51(T) (98.96%) according to the EzTaxon server result (<https://eztaxon-e.ezbiocloud.net/>).⁴⁷

For the cultivation of the strain CA-297274, a first seed culture was prepared by inoculating 10 mL of seed medium (ATCC-2) which consists of soluble starch (20 g/L), dextrose (10 g/L), NZ amine EKC (Sigma) (5 g/L), Difco beef extract (3 g/L), Bacto peptone (5 g/L), yeast extract (5 g/L), and CaCO₃ (1 g/L), adjusted to pH 7.0 with NaOH before addition of CaCO₃, in a 50 mL tube with frozen agar plugs of the producing strain and incubating the tube at 28 °C with shaking at 220 rpm for about 48 h. A second seed culture was prepared by inoculating 50 mL of seed medium in a 250 mL flask with 2.5 mL of the first seed. A 5% aliquot of the second seed culture was transferred to eight 500 mL flasks filled with 125 mL each of the production medium M016 which consisted of glucose (10 g/L), soluble starch from potato (10 g/L), maltose (10 g/L), soytone peptone (5 g/L), tryptone (4 g/L), yeast extract (1 g/L), KH₂PO₄ (0.1 g/L), K₂HPO₄ (0.2 g/L), MgSO₄·7H₂O (0.05 g/L), NaCl (0.02 g/L), CaCl₂·2H₂O (0.05 g/L), and 1 mL of trace salts solution (SnCl₂ (0.005 g/L), H₃BO₃ (0.01 g/L), NaMoO₄ (0.012 g/L), CuSO₄ (0.015 g/L), CoCl₂ (0.02 g/L), KCl (0.02 g/L), ZnCl₂ (0.02 g/L), MnSO₄ (0.1 g/L), HCl (2 mL), and FeCl₃ (5.8 g/L)), pH 5.8, and the vials were incubated at 28 °C for 7 days in a rotary shaker at 220 rpm and 70% humidity before harvesting.

Isolation and Identification of Glycinocins. A 1.0 L fermentation of the strain CA-297274 was extracted by the addition

of an equal volume of acetone and agitation at 200 rpm for 180 min. The mixture was centrifuged, and the pellet was discarded. The acetone was evaporated under a N₂ stream at room temperature. The aqueous residue was loaded onto a HP20 resin column (14 g, 140 × 15 mm²) and was eluted with acetone, MeOH, and DMSO. Acetone and MeOH eluates were pooled and subjected to preparative reverse-phase chromatography (Agilent Zorbax SB-C₁₈, 21.2 × 250 mm², 7 μm) applying gradient elution and H₂O–CH₃CN with 0.1% TFA as mobile phase (3.6 mL/min; 50% to 100% CH₃CN for 40 min; UV detection at 210 nm). Compounds 1–4 were eluted within a retention time range of 9.0 to 13.0 minutes. Fractions containing each of these four compounds of interest were pooled and further purified by semi-preparative RP-HPLC (Agilent Zorbax, RX-C₁₈, 10 × 150 mm², 5 μm) applying gradient elution with H₂O–CH₃CN as mobile phase (3.6 mL/min; 40% to 60% CH₃CN for 40 min; UV detection at 210 nm). Elution times for the compounds were 15.0, 22.0, 25.0, and 27.0 min for 1–4. The organic solvent was evaporated under a N₂ stream, and the resulting aqueous solution was freeze-dried. Compounds 1–4 were thus obtained as amorphous white powder in all cases (10.2 mg, 8.7 mg, 12.3 mg, and 6.0 mg of 1–4, respectively).

Glycinocin E (1): white amorphous solid; α_{D}^{25} –16.5 (c 0.2, MeOH); IR (ATR) ν_{max} 3299, 3069, 2927, 1660, 1537, 1432, and 1194 cm^{–1}; ¹H and ¹³C NMR data see Table 1; (+)-HR-ESIMS *m/z* 1231.6567 [M + H]⁺ (calcd for C₅₇H₉₁N₁₂O₁₈⁺, 1231.6574).

Glycinocin F (2): white amorphous solid; α_{D}^{25} –5.0 (c 0.2, MeOH); IR (ATR) ν_{max} 3301, 3073, 2929, 1666, 1536, 1443, and 1192 cm^{–1}; ¹H and ¹³C NMR data see Table 1; (+)-HR-ESIMS *m/z* 1245.6710 [M + H]⁺ (calcd for C₅₈H₉₃N₁₂O₁₈⁺, 1245.6730).

Glycinocin G (3): white amorphous solid; α_{D}^{25} –13.0 (c 0.1, MeOH); IR (ATR) ν_{max} 3306, 3073, 2929, 2855, 1660, 1535, 1446, 1244, and 1201 cm^{–1}; ¹H and ¹³C NMR data see Table 2; (+)-HR-ESIMS *m/z* 1259.6883 [M + H]⁺ (calcd for C₅₉H₉₅N₁₂O₁₈⁺, 1259.6887).

Glycinocin H (4): white amorphous solid; α_{D}^{25} –17.7 (c 0.1, MeOH); IR (ATR) ν_{max} 3294, 3071, 2928, 1656, 1529, and 1199 cm^{–1}; ¹H and ¹³C NMR data see Table 2; (+)-HR-ESIMS *m/z* 1273.7018 [M + H]⁺ (calcd for C₆₀H₉₇N₁₂O₁₈⁺, 1273.7043).

Marfey's Analysis of Glycinocins. A sample of compound 1 (0.1 mg) was dissolved in 0.1 mL of 6 N HCl and heated at 80 °C for 16 hours. The resulting crude hydrolysate was dried under a N₂ stream and resuspended in 100 μL of water. The solution was neutralized with 20 μL of a NaHCO₃ 1 M solution, and 0.1 mL of L-FDVA (Marfey's reagent, *N*-(2,4-dinitro-5-fluorophenyl)-L-valinamide) in acetone (10 mg/mL) was added. This step was repeated with solutions of each amino acid standard (D, L, or DL mixture). The reaction mixtures were incubated at 40 °C for 80 min, then quenched by adding 20 μL of a 1 N HCl solution. For the HPLC analysis, 10 μL of the derivative solution was added to 40 μL of acetonitrile and analyzed by HPLC/MS on an Agilent 1260 Infinity II single quadrupole instrument. Separations were carried out on a Waters X-Bridge C18 column (4.6 × 150 mm², 5 μm) using a mobile phase consisting of a mixture of two solvents, H₂O–CH₃CN, both containing 0.1% TFA, and a linear gradient of 25% to 55% CH₃CN + 0.1% TFA over 50 min with a flow rate of 1.0 mL/min. The retention times of the L-FDVA derivatives of the different amino acid standards were as follows: D-Asp: 10.08; L-Asp: 8.49; D-Dap: 33.32; L-Dap: 31.93; D-Ile: 38.97; L-Ile: 24.37; D-Pipe: 24.71; L-Pipe: 27.70; D-Pro: 18.32; L-Pro: 13.43; D-Val: 31.03; L-Val: 18.94. The retention time of the peaks from the L-FDVA derivatives of the hydrolysate of 1 were as follows: L-Asp: 8.48; L-Pro: 13.41; L-Ile: 24.44; D-Pipe: 24.64; L-Dap: 32.09; D-Val: 32.23.

Genome Sequencing and Bioinformatic Analysis. Genomic DNA from strain *Streptomyces* sp. CA-297274 was extracted and purified following a protocol previously described⁴⁸ from cultures grown in the ATCC-2 seed medium. De novo whole genome sequencing of the strain was carried out using a combination of paired-end Illumina sequencing and single molecule long-read PacBio sequencing (Macrogen, Seoul, Korea). PacBio reads were assembled with Flye, and Illumina reads were then employed to polish the

genome using Pilon, obtaining a single contig with 9,719,504 bp and 70.4 % GC content.

The draft genome was analyzed using antiSMASH 6.1.1 to identify putative biosynthetic gene clusters. Only one of the regions identified by antiSMASH matched the requirements, in terms of the number of NRPS modules and specificities of the adenylation domains, expected for the biosynthesis of glycinocins E–H.

Antifungal Activity. The evaluation of the antifungal activity was carried out using phytopathogenic strain *Zymoseptoria tritici* CBS 115943. The microdilution assay was performed from conidia solution (1×10^6 conidia/mL) obtained after culturing *Z. tritici* CBS 115943 on YM agar plates for 7 days. This conidia solution was incubated in 96 well plates with pure compounds in an RPMI liquid-based assay for 120 h at 25 °C, and activities were scored using absorbance differences at 600 nm between the final and the initial incubation times as an indicator of growth inhibition and resazurin fluorescence as an indicator of cell viability. Pure compounds were tested in 2-fold dilutions (10 points) starting at 160 µg/mL, except for 4, whose curve started at 20 µg/mL, dissolved in 100% DMSO and 2 µL of each point was dispensed in each assay plate in triplicate. IC₅₀ values (dose/concentration that induces half-maximum response) were calculated based on the dose–response curves obtained from both readouts. The results obtained were analyzed using Genedata Screener software (Genedata Inc., Basel, Switzerland).

Antibacterial Activity. The antibacterial activity was evaluated by microdilution assays with and without the addition of CaCl₂ (3 mM) using the Gram-positive bacteria vancomycin-resistant *Enterococcus faecium* (VRE-VanA ATCC 15167) and methicillin-resistant *Staphylococcus aureus* (MRSA MB5393). Thawed stock inocula suspensions from cryovials of each microorganism (MRSA or VRE-VanA) were inoculated into 25 mL of Brain Heart Infusion broth (BHI 37 g/L) in 250 mL Erlenmeyer flasks and incubated overnight at 37 °C shaking at 220 rpm and then diluted in order to obtain assay inocula of 1.1×10^6 CFU/mL (MRSA) or 5×10^5 CFU/mL (*E. faecium* VAN A). Using 96-well plates, 90 µL/well of the diluted inoculum was mixed with 1.6 µL/well of each compound dissolved in DMSO and 8.4 µL/well of BHI medium. Daptomycin was used as the assay control with and without the addition of CaCl₂ (3 mM). Absorbance at 612 nm was measured with an Envision spectrophotometer at T₀ (zero time), and immediately after that, plates were statically incubated at 37 °C for 18–20 hours. After this period, the assay plates were shaken, and once more, the absorbance was measured at T_f (final time). Percentage inhibition of growth was calculated using the following equation:

$$\% \text{ Inhibition} = 100 \times \frac{1 - [(T_{f,\text{sample}} - T_{0,\text{sample}}) - (T_{f,\text{blank}} - T_{0,\text{blank}})]}{[(T_{f,\text{growth}} - T_{0,\text{growth}}) - (T_{f,\text{blank}} - T_{0,\text{blank}})]}$$

The data were analyzed using Genedata Screener software (Genedata Inc., Basel, Switzerland).

Cytotoxicity. Pure compounds (1–4) were tested against 5 human cancer cell lines, A549 (ATCC CCL-185), A2058 (ATCC CRL-3601), HepG2 (ATCC HB-8065), MCF7 (DSMZ ACC 115), and MIA PaCa-2 (ATCC CRL-1420), by means of an MTT viability assay. Compounds were assayed in triplicate as 10-point curves with 1/2 dilution starting at 40 µg/mL, except for 4, whose curve started at 5 µg/mL. A549, A2058, and MIA PaCa-2 cells were seeded at 4000 cells/well, whereas HepG2 and MCF7 cells were seeded at 8000 cells/well in 384-well plates (Corning 3701) and incubated overnight at 37 °C and 5% CO₂. Nanoliters of the corresponding concentrations of pure compounds were added by means of a Beckman Echo 550,⁴⁹ and cells were further incubated for 72 hours. MMS (methylmethanesulfonate, Sigma-Aldrich 129925), 2 mM, was used as positive control, and DMSO 0.5% was used as the negative control. Finally, MTT dye (thiazolyl blue tetrazolium bromide, ACROS Organics 158990050, 0.5 mg/mL) was added to each well, cells were incubated for 2–3 h, supernatant was removed, 25 µL of DMSO (100%) was added, and absorbance was measured at 570 nm. The results obtained were analyzed using Genedata Screener software (Genedata Inc., Basel, Switzerland).

■ ASSOCIATED CONTENT

Data Availability Statement

1D/2D NMR spectra for compounds 1–4 have been deposited to the NP-MRD database (NP0350612, NP0350613, NP0350614, and NP0350615).

Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acs.jnatprod.5c00740>.

General information of fermentation; HR-ESIMS and HR-ESIMS/MS; ¹H, ¹³C, and bidimensional NMR, COSY, TOCSY, NOESY, HSQC, and HMBC correlations; LC-MS results from the Marfey's analysis, IC₅₀ tables of antimicrobial activities (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Ignacio Fernández-Pastor – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España;

orcid.org/0000-0003-1729-0860;

Email: ignacio.fernandez@medinaandalucia.es

Fernando Reyes – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España; orcid.org/0000-0003-1607-5106; Email: fernando.reyes@medinaandalucia.es

Authors

Victor González-Menéndez – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España

Ignacio González – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España

Pilar Sanchez – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España; orcid.org/0000-0002-6034-1857

Rachel Serrano – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España

Thomas A Mackenzie – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España

Daniel Oves-Costales – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España

Manuel Casares Porcel – Departamento de Botánica, Facultad de Farmacia, Universidad de Granada, 18071 Granada, España

Olga Genilloud – Fundación MEDINA, Parque Tecnológico Ciencias de la Salud, 18016 Granada, España; orcid.org/0000-0002-4202-1219

Complete contact information is available at: <https://pubs.acs.org/doi/10.1021/acs.jnatprod.5c00740>

Funding

Financial support was received from the Junta de Andalucía through grant number PY18-RE-0027. The polarimeter, HPLC, IR, NMR equipment, and plate reader used in this work were purchased via grants for scientific and technological infrastructures from the Ministerio de Ciencia e Innovación [Grant Nos. PCT-010000-2010-4 (NMR), INP-2011-0016-PCT-010000 ACT6 (polarimeter, HPLC, and IR), and PCT-01000-ACT7, 2011-13 (plate reader)].

Notes

The authors declare no competing financial interest.

REFERENCES

- (1) Patel, S.; Ahmed, S.; Eswari, J. S. *World J Microbiol Biotechnol* **2015**, *31* (8), 1177–1193.
- (2) Pirri, G.; Giuliani, A.; Nicoletto, S. F.; Pizzuto, L.; Rinaldi, A. C. *Cent Eur J Biol* **2009**, *4* (3), 258–273.
- (3) Cochrane, S. A.; Vederas, J. C. *Med Res Rev* **2016**, *36* (1), 4–31.
- (4) Bodanszky, M.; Sigler, G. F.; Bodanszky, A. *J Am Chem Soc* **1973**, *95* (7), 2352–2357.
- (5) Baltz, R. H.; Miao, V.; Wrigley, S. K. *Nat Prod Rep* **2005**, *22* (6), 717–741.
- (6) Hover, B. M.; Kim, S. H.; Katz, M.; Charlop-Powers, Z.; Owen, J. G.; Ternei, M. A.; Maniko, J.; Estrela, A. B.; Molina, H.; Park, S.; Perlin, D. S.; Brady, S. F. *Nature Microbiology* **2018**, *3* (4), 415–422.
- (7) Zhang, S.; Chen, Y.; Zhu, J.; Lu, Q.; Cryle, M. J.; Zhang, Y.; Yan, F. *Nat Prod Rep* **2023**, *40* (3), 557–594.
- (8) Zhao, H.; Shao, D.; Jiang, C.; Shi, J.; Li, Q.; Huang, Q.; Rajoka, R.; Yang, H.; Jin, M. *Appl Microbiol Biotechnol* **2017**, *101*, S951.
- (9) Frankmolle, W. P.; Larsen, L. K.; Caplan, F. R.; Patterson, G. M. L.; Knubel, G.; Levine, I. A.; Moore, R. E. *J Antibiot (Tokyo)* **1992**, *45* (9), 1451–1457.
- (10) Kakinuma, A.; Hori, M.; Sugino, H.; Yoshida, I.; Isono, M.; Tamura, G.; Arima, K. *Agric Biol Chem* **1969**, *33* (10), 1523–1524.
- (11) Neuhoof, T.; Schmieder, P.; Preussel, K.; Dieckmann, R.; Pham, H.; Bartl, F.; Von Döhren, H. *J Nat Prod* **2005**, *68* (5), 695–700.
- (12) Schwartz, R. E.; Giacobbe, R. A.; Bland, J. A.; Monaghan, R. L. *J Antibiot (Tokyo)* **1989**, *42*, 163.
- (13) Bionda, N.; Pitteloud, J. P.; Cudic, P. *Future Med Chem* **2013**, *5* (11), 1311–1330.
- (14) Fewer, D. P.; Jokela, J.; Heinilä, L.; Aesoy, R.; Sivonen, K.; Galica, T.; Hrouzek, P.; Herfindal, L. *Physiol Plant* **2021**, *173* (2), 639–650.
- (15) Silverman, J. A.; Perlmutter, N. G.; Shapiro, H. M. *Antimicrob Agents Chemother* **2003**, *47* (8), 2538.
- (16) Pogliano, J.; Pogliano, N.; Silverman, J. A. *J Bacteriol* **2012**, *194* (17), 4494.
- (17) Fewer, D. P.; Jokela, J.; Heinilä, L.; Aesoy, R.; Sivonen, K.; Galica, T.; Hrouzek, P.; Herfindal, L. *Physiol Plant* **2021**, *173* (2), 639–650.
- (18) Strieker, M.; Marahiel, M. A. *ChemBioChem* **2009**, *10* (4), 607–616.
- (19) Lakey, J. H.; Maget-Dana, R.; Ptak, M. *Biochim Biophys Acta* **1989**, *985* (1), 60–66.
- (20) Kleijn, L. H. J.; Vlieg, H. C.; Wood, T. M.; Sastre Torano, J.; Janssen, B. J. C.; Martin, N. I. *Angewandte Chemie - International Edition* **2017**, *56* (52), 16546–16549.
- (21) Wu, C.; Shang, Z.; Lemetre, C.; Ternei, M. A.; Brady, S. F. *J Am Chem Soc* **2019**, *141* (9), 3910–3919.
- (22) Honrubia, M.; Cano, A.; Molina-Niñirola, C. *Persoonia* **1992**, *14*, 647.
- (23) Menéndez-Serra, M.; Triadó-Margarit, X.; Castañeda, C.; Herrero, J.; Casamayor, E. O. *Science of The Total Environment* **2019**, *650*, 343–353.
- (24) Pelaez, F.; Collado, J.; Arenal, F.; Basilio, A.; Cabello, A.; Diez Matas, M. T.; Garcia, J. B.; Gonzalez Del Val, A.; Gonzalez, V.; Gorrochategui, J.; Hernández, P.; Martin, I.; Platas, G.; Vicente, F. *Mycol Res* **1998**, *102* (6), 755–761.
- (25) Wierzechos, J.; De Los Ríos, A.; Ascaso, C. *INTERNATIONAL MICROBIOLOGY* **2012**, *15*, 173–183.
- (26) Ziko, L.; Adel, M.; Malash, M. N.; Siam, R. *Marine Drugs* **2019**, *17* (5), 273.
- (27) Roy, B.; Maitra, D.; Ghosh, J.; Mitra, A. K. *Microbes and Microbial Biotechnology for Green Remediation* **2022**, 287–304.
- (28) Tse, C.; Ma, K. *Grand Challenges in Biology and Biotechnology* **2016**, *1*, 1–46.
- (29) Kong, F.; Carter, G. T. *J Antibiot (Tokyo)* **2003**, *56* (6), 557–564.
- (30) CHEMnetBASE. <https://dnp.chemnetbase.com/chemical/ChemicalSearch.xhtml?dswid=6603> (accessed 2023-10-18).
- (31) Sorokina, M.; Merseburger, P.; Rajan, K.; Yirik, M. A.; Steinbeck, C. *J. Cheminf.* **2021**, *13* (1), 2.
- (32) Wang, M.; Carver, J. J.; Phelan, V. V.; Sanchez, L. M.; Garg, N.; Peng, Y.; Nguyen, D. D.; Watrous, J.; Kapono, C. A.; Luzzatto-Knaan, T.; Porto, C.; Bouslimani, A.; Melnik, A. V.; Meehan, M. J.; Liu, W. T.; Crusemann, M.; Boudreau, P. D.; Esquenazi, E.; Sandoval-Calderón, M.; Kersten, R. D.; Pace, L. A.; Quinn, R. A.; Duncan, K. R.; Hsu, C. C.; Floros, D. J.; Gavilan, R. G.; Kleigrew, K.; Northen, T.; Dutton, R. J.; Parrot, D.; Carlson, E. E.; Aigle, B.; Michelsen, C. F.; Jelsbak, L.; Sohlenkamp, C.; Pevzner, P.; Edlund, A.; McLean, J.; Piel, J.; Murphy, B. T.; Gerwick, L.; Liaw, C. C.; Yang, Y. L.; Humpf, H. U.; Maansson, M.; Keyzers, R. A.; Sims, A. C.; Johnson, A. R.; Sidebottom, A. M.; Sedio, B. E.; Klitgaard, A.; Larson, C. B.; Boya, C. A. P.; Torres-Mendoza, D.; Gonzalez, D. J.; Silva, D. B.; Marques, L. M.; Demarque, D. P.; Pociute, E.; O'Neill, E. C.; Briand, E.; Helfrich, E. J. N.; Granatosky, E. A.; Glukhov, E.; Ryffel, F.; Houson, H.; Mohimani, H.; Kharbush, J. J.; Zeng, Y.; Vorholt, J. A.; Kurita, K. L.; Charusanti, P.; McPhail, K. L.; Nielsen, K. F.; Vuong, L.; Elfeki, M.; Traxler, M. F.; Engene, N.; Koyama, N.; Vining, O. B.; Baric, R.; Silva, R. R.; Mascuch, S. J.; Tomasi, S.; Jenkins, S.; Macherla, V.; Hoffman, T.; Agarwal, V.; Williams, P. G.; Dai, J.; Neupane, R.; Gurr, J.; Rodriguez, A. M. C.; Lamsa, A.; Zhang, C.; Dorrestein, K.; Duggan, B. M.; Almaliti, J.; Allard, P. M.; Phapale, P.; Nothias, L. F.; Alexandrov, T.; Litaudon, M.; Wolfender, J. L.; Kyle, J. E.; Metz, T. O.; Peryea, T.; Nguyen, D. T.; VanLeer, D.; Shinn, P.; Jadhav, A.; Müller, R.; Waters, K. M.; Shi, W.; Liu, X.; Zhang, L.; Knight, R.; Jensen, P. R.; Palsson, B.; Pogliano, K.; Linington, R. G.; Gutiérrez, M.; Lopes, N. P.; Gerwick, W. H.; Moore, B. S.; Dorrestein, P. C.; Bandeira, N. *Nature Biotechnology* **2016**, *34* (8), 828–837.
- (33) Borders, D. B.; Leese, R. A.; Jarolmen, H.; Francis, N. D.; Fantini, A. A.; Falla, T.; Fiddes, J. C.; Aumelas, A. *J Nat Prod* **2007**, *70* (3), 443–446.
- (34) Kessler, H. *Angewandte Chemie International Edition in English* **1982**, *21* (7), 512–523.
- (35) Zhou, C. C.; Stewart, K. D.; Dhaon, M. K. *Magnetic Resonance in Chemistry* **2005**, *43* (1), 41–46.
- (36) Lin, Z.; Flores, M.; Forteza, I.; Henriksen, N. M.; Concepcion, G. P.; Rosenberg, G.; Haygood, M. G.; Olivera, B. M.; Light, A. R.; Cheatham, T. E.; Schmidt, E. W. *J Nat Prod* **2012**, *75* (4), 644–649.
- (37) Lu, Z.; Van Wagoner, R. M.; Harper, M. K.; Baker, H. L.; Hooper, J. N. A.; Bewley, C. A.; Ireland, C. M. *J Nat Prod* **2011**, *74* (2), 185–193.
- (38) Tyurin, A. P.; Alferova, V. A.; Paramonov, A. S.; Shuvalov, M. V.; Malanicheva, I. A.; Grammatikova, N. E.; Solyev, P. N.; Liu, S.; Sun, C.; Prokhorenko, I. A.; Efimenko, T. A.; Terekhova, L. P.; Efremenkova, O. V.; Shenkarev, Z. O.; Korshun, V. A. *Medchemcomm* **2018**, *9* (4), 667–675.
- (39) Wang, Y.; Chen, Y.; Shen, Q.; Yin, X. *Gene* **2011**, *483* (1–2), 11–21.
- (40) Corcilius, L.; Elias, N. T.; Ochoa, J. L.; Linington, R. G.; Payne, R. J. *Journal of Organic Chemistry* **2017**, *82* (23), 12778–12785.
- (41) van den Berg, F.; Paveley, N. D.; van den Bosch, F. *Plant Pathol* **2016**, *65* (8), 1380–1389.
- (42) Corcilius, L.; Elias, N. T.; Ochoa, J. L.; Linington, R. G.; Payne, R. J. *Journal of Organic Chemistry* **2017**, *82* (23), 12778–12785.
- (43) Wood, T. M.; Martin, N. I. *Medchemcomm* **2019**, *10* (5), 634–646.
- (44) Yin, N.; Li, J.; He, Y.; Herradura, P.; Pearson, A.; Mesleh, M. F.; Mascio, C. T.; Howland, K.; Steenbergen, J.; Thorne, G. M.; Citron, D.; Van Praagh, A. D. G.; Mortin, L. I.; Keith, D.; Silverman, J.; Metcalf, C. *J Med Chem* **2015**, *58* (12), 5137–5142.
- (45) D'Costa, V. M.; Mukhtar, T. A.; Patel, T.; Koteva, K.; Waglechner, N.; Hughes, D. W.; Wright, G. D.; De Pascale, G. *Antimicrob Agents Chemother* **2012**, *56* (2), 757.
- (46) Chiou, S.-L.; Chang, C.-Y.; Chu, J. *ChemMedChem* **2025**, *20*, e202400498.
- (47) Chalita, M.; Kim, Y. O.; Park, S.; Oh, H. S.; Cho, J. H.; Moon, J.; Baek, N.; Moon, C.; Lee, K.; Yang, J.; Nam, G. G.; Jung, Y.; Na, S. I.; Bailey, M. J.; Chun, J. *Int J Syst Evol Microbiol* **2024**, *74* (6), 6421.

(48) Kieser, T.; Bibb, M.; Chater, K.; Butter, M.; Hopwood, D.; Bittner, M.; Buttner, M. *Practical Streptomyces Genetics: A Laboratory Manual*; 2000.

(49) Mackenzie, T. A.; Tormo, J. R.; Cautain, B.; Martínez, G.; Sánchez, I.; Genilloud, O.; Vicente, F.; Ramos, M. C. *SLAS Technol* **2024**, 29 (3), No. 100111.



CAS BIOFINDER DISCOVERY PLATFORM™

CAS BIOFINDER HELPS YOU FIND YOUR NEXT BREAKTHROUGH FASTER

Navigate pathways, targets, and
diseases with precision

Explore CAS BioFinder

